Overview

Memantine for Epileptic Encephalopathy

Status:
Recruiting
Trial end date:
2022-05-31
Target enrollment:
0
Participant gender:
All
Summary
This study will evaluate the potential benefit of memantine hydrochloride as treatment for children with epileptic encephalopathy using a double-blind placebo-controlled cross-over design.
Phase:
Phase 4
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Kenneth Myers, MD
Treatments:
Memantine
Criteria
Inclusion Criteria:

- Written informed consent obtained

- Age 6-18 years (Weight ≥ 20 kg)

- Clinical diagnosis of epileptic encephalopathy

- Subject with epilepsy and developmental impairment;

- Epileptic activity itself contributes to severe cognitive and behavioural
impairments

- Patients will typically have already have trialed at least two standard therapies

- Females of childbearing age:

- Negative urinary pregnancy test at screening

- Agree to use effective contraception for the duration of the study

Exclusion Criteria:

- Inability of a parent or legal guardian to give informed consent for any reason.

- Known hypersensitivity to memantine hydrochloride

- Taking concomitant Amantadine, Ketamine or Dextromethorphan, Cimetidine, Ranitidine,
Procainamide, Quinidine, Quinine, Hydrochlorothiazide, Anticholinergics, L-dopa,
Anticoagulant,

- Any degree of renal impairment